Aprimo provides technology solutions for content, operations, and performance that enable enterprises to optimize their brand experiences and the resources they use to deliver them. Our platform gives enterprises the advantage by streamlining and governing all the behind-the-scenes activities – from ideation to distribution – involved in delivering exceptional brand experiences.

C-Suite On Deck

Q&A with Ed Breault, Chief Marketing Officer at Aprimo

Events

Related News

Business Insights

AQEMIA ANNOUNCES PILOT STUDY WITH JANSSEN TO UTILIZE AQEMIA’S PHYSICS-DRIVEN DRUG DISCOVERY TECHNOLOGY

Aqemia | February 15, 2022

news image

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum-inspired physics announces it has entered into a pilot study agreement with Janssen. Through the agreement Aqemia’s unique technology to predict the potency of small molecules for a given target based on physics-based calculations will be applied to selected Janssen datasets. The agreement aims at building a common understanding of the performance of Aqemia’s technolog...

Read More

Business Insights

ARS PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM WITH ADDITION OF PHARMACEUTICAL COMMERCIALIZATION VETERANS

ARS Pharmaceuticals, Inc. | February 10, 2022

news image

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive vice president, commercial strategy and Daniel Relovsky as senior vice president, sales and marketing. Mr. Kaplan and Mr. Relovsky, accomplished industry veterans with proven track r...

Read More

Business Insights

HARROW HEALTH ACQUIRES OPHTHALMIC SURGICAL DRUG CANDIDATE FROM WAKAMOTO PHARMACEUTICAL CO., LTD.

Harrow Health, Inc. | August 18, 2021

news image

Harrow Health, Inc. an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan’s Ministry of Health Labor and Welfare (or MHLW) approval, MaQaid was launched in Japan in 2010, ...

Read More

Business Insights, PHARMACY MARKET

HOVIONE AND LAXXON MEDICAL ESTABLISH AN AGREEMENT FOR THE CGMP PRODUCTION OF 3D SCREEN PRINTED PHARMACEUTICAL APPLICATIONS

PRNewswire | March 23, 2023

news image

Hovione and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry. This partnership combines Laxxon´s expertise in 3D screen printing, based on their SPID®-Technology, with Hovione's product & process development, engineering and manufacturing expertise in pharmaceutical applications. Under the terms of the agreement, Hovione will establish the Laxxon Medical 3D screen printing technology a...

Read More
news image

Business Insights

AQEMIA ANNOUNCES PILOT STUDY WITH JANSSEN TO UTILIZE AQEMIA’S PHYSICS-DRIVEN DRUG DISCOVERY TECHNOLOGY

Aqemia | February 15, 2022

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum-inspired physics announces it has entered into a pilot study agreement with Janssen. Through the agreement Aqemia’s unique technology to predict the potency of small molecules for a given target based on physics-based calculations will be applied to selected Janssen datasets. The agreement aims at building a common understanding of the performance of Aqemia’s technolog...

Read More
news image

Business Insights

ARS PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM WITH ADDITION OF PHARMACEUTICAL COMMERCIALIZATION VETERANS

ARS Pharmaceuticals, Inc. | February 10, 2022

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive vice president, commercial strategy and Daniel Relovsky as senior vice president, sales and marketing. Mr. Kaplan and Mr. Relovsky, accomplished industry veterans with proven track r...

Read More
news image

Business Insights

HARROW HEALTH ACQUIRES OPHTHALMIC SURGICAL DRUG CANDIDATE FROM WAKAMOTO PHARMACEUTICAL CO., LTD.

Harrow Health, Inc. | August 18, 2021

Harrow Health, Inc. an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan’s Ministry of Health Labor and Welfare (or MHLW) approval, MaQaid was launched in Japan in 2010, ...

Read More
news image

Business Insights, PHARMACY MARKET

HOVIONE AND LAXXON MEDICAL ESTABLISH AN AGREEMENT FOR THE CGMP PRODUCTION OF 3D SCREEN PRINTED PHARMACEUTICAL APPLICATIONS

PRNewswire | March 23, 2023

Hovione and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry. This partnership combines Laxxon´s expertise in 3D screen printing, based on their SPID®-Technology, with Hovione's product & process development, engineering and manufacturing expertise in pharmaceutical applications. Under the terms of the agreement, Hovione will establish the Laxxon Medical 3D screen printing technology a...

Read More